{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "HIV",
      "STING agonists",
      "cellular immunity",
      "coronavirus",
      "cyclic dinucleotides",
      "cytotoxic T cells",
      "influenza",
      "nanoparticles",
      "neutralizing antibody",
      "stimulator of interferon genes"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33252301",
  "DateCompleted": {
    "Year": "2021",
    "Month": "01",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "11",
        "Day": "30"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.2217/nnm-2020-0269"
    ],
    "Journal": {
      "ISSN": "1748-6963",
      "JournalIssue": {
        "Volume": "15",
        "Issue": "29",
        "PubDate": {
          "Year": "2020",
          "Month": "Dec"
        }
      },
      "Title": "Nanomedicine (London, England)",
      "ISOAbbreviation": "Nanomedicine (Lond)"
    },
    "ArticleTitle": "Nanomedicinal delivery of stimulator of\u00a0interferon genes agonists: recent advances in virus vaccination.",
    "Pagination": {
      "StartPage": "2883",
      "EndPage": "2894",
      "MedlinePgn": "2883-2894"
    },
    "Abstract": {
      "AbstractText": [
        "The discovery of stimulator of\u00a0interferon genes (STING) and their agonists as primary components that link antiviral innate and adaptive immunity has motivated growing research on STING agonist-mediated immunotherapy and vaccine development. To overcome the delivery challenge in shuttling highly polar STING agonists, typically in the form of cyclic dinucleotides, to target cells and to STING proteins\u00a0in cellular cytosol, numerous nanoformulation strategies have been implemented for effective STING activation. While many STING-activating nanoparticles are developed to enhance anticancer immunotherapy, their adoption as vaccine adjuvant has\u00a0vastly propelled antiviral\u00a0vaccination efforts against challenging public health threats, including HIV, influenza and coronaviruses. In light of the COVID-19 pandemic that has thrusted vaccine development into the public spotlight, this review highlights advances in nanomedicinal STING agonist delivery with an emphasis on their applications in antiviral vaccination."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming University & Academic Sinica, Taipei 11529, Taiwan."
          },
          {
            "Identifier": [],
            "Affiliation": "Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan."
          }
        ],
        "LastName": "Chattopadhyay",
        "ForeName": "Saborni",
        "Initials": "S"
      },
      {
        "Identifier": [
          "0000-0002-0988-7029"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming University & Academic Sinica, Taipei 11529, Taiwan."
          },
          {
            "Identifier": [],
            "Affiliation": "Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan."
          },
          {
            "Identifier": [],
            "Affiliation": "Center of Applied Nanomedicine, National Cheng Kung University, Tainan 701, Taiwan."
          }
        ],
        "LastName": "Hu",
        "ForeName": "Che-Ming Jack",
        "Initials": "CJ"
      }
    ],
    "GrantList": [
      {
        "GrantID": "106-2119-M-001-010, 107-2119-M-001-042, 108-2119-M",
        "Agency": "MOST, Taiwan",
        "Country": "International"
      },
      {
        "GrantID": "AS-CDA-105-L06",
        "Agency": "Academia Sinica",
        "Country": "International"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Nanomedicine (Lond)",
    "NlmUniqueID": "101278111",
    "ISSNLinking": "1743-5889"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "pathology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "immunology",
        "therapeutic use"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Immunity, Innate"
    },
    {
      "QualifierName": [
        "trends"
      ],
      "DescriptorName": "Immunotherapy"
    },
    {
      "QualifierName": [
        "chemistry",
        "therapeutic use"
      ],
      "DescriptorName": "Nanoparticles"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Signal Transduction"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}